Skip to main content
PEPTARA LABS
Get Started

Head to head

Tirzepatide vs Ozempic: How the Fat-Loss Trials Compare

Published by · Updated · How we research and check our pages

Mounjaro / Zepbound (tirzepatide) vs Ozempic / Wegovy (semaglutide). Both FDA-approved as brand pens. Tirzepatide is a dual-agonist (GLP-1 + GIP); semaglutide is single-agonist GLP-1. Different trials, not head-to-head in obesity.

Verdict in 4 lines

  • Tirzepatide hit -22.5% body weight in SURMOUNT-1 (Phase 3, 72 weeks).
  • Semaglutide hit -14.9% in STEP-1 (Phase 3, 68 weeks).
  • Different trials, different cohorts. Treat the gap as a data observation, not a head-to-head finding.
  • Peptara does NOT sell semaglutide. Brand semaglutide pens are prescription-only, and their price depends on insurance and pharmacy.

TL;DR comparison

One table, every row that matters. Each weight figure comes from a named trial.

Tirzepatide
Ozempic / Wegovy (semaglutide)
Class
Dual agonist (GLP-1 + GIP)
Single agonist (GLP-1 only)
Mechanism
Activates two appetite + metabolic receptors
Activates one appetite receptor (GLP-1)
FDA status
Mounjaro FDA-approved 2022 (T2D). Zepbound FDA-approved 2023 (obesity).
Ozempic FDA-approved 2017 (T2D). Wegovy FDA-approved 2021 (obesity).
Trial peak weight loss
-22.5% (highest dose group), Phase 3 SURMOUNT-1, 72 weeks (NEJM 2022)
-14.9%, Phase 3 STEP-1, 68 weeks (NEJM 2021)
Manufacturer
Eli Lilly
Novo Nordisk
Format sold
Brand pre-filled pens (Mounjaro / Zepbound via prescription)
Brand pre-filled pens (Ozempic / Wegovy via prescription)
Side effects
GI (nausea, diarrhea), dose-dependent. SURMOUNT-1 trial well-characterized.
GI (nausea, diarrhea), well-characterized over years of clinical use

Mechanism: dual GLP-1 + GIP vs single GLP-1

Both compounds activate the GLP-1 satiety and insulin axis. Tirzepatide adds a second receptor.

Tirzepatide (dual agonist)

Targets two receptor systems: the standard GLP-1 satiety and insulin axis (slows gastric emptying, reduces appetite) plus GIP (glucose-dependent insulinotropic polypeptide), which appears to add fat-mass-loss benefit on top of GLP-1 alone. Sold as Mounjaro (T2D, FDA 2022) and Zepbound (obesity, FDA 2023) brand pens.

Semaglutide (single GLP-1 agonist)

Targets one receptor system (GLP-1 only). Mature clinical data spans more than 10 years through Ozempic and Wegovy trials, including SUSTAIN (T2D cardiovascular) and SELECT (obesity cardiovascular outcomes). Sold as Ozempic (T2D, FDA 2017) and Wegovy (obesity, FDA 2021) brand pens. Peptara does not sell semaglutide.

Honest trade-off: more receptor activation drives a stronger fat-loss signal in Phase 3 trials, but semaglutide has the longer real-world safety record. For the GLP-1 + GIP + glucagon triple-agonist (Retatrutide), see Retatrutide vs Tirzepatide.

Clinical trial results

Headline figures, trial citations, and the disclaimer that has to come with them.

Tirzepatide Phase 3 (SURMOUNT-1)

  • Reference: Jastreboff et al, NEJM 2022;387(3):205-216
  • Phase: 3
  • n: 2,539 (no T2D)
  • Duration: 72 weeks
  • Highest dose group: -22.5% mean body weight
  • Middle dose group: -21.4% · Lowest dose group: -16.0% · Placebo: -2.4% (efficacy estimand)

Semaglutide Phase 3 (STEP-1)

  • Reference: Wilding et al, NEJM 2021;384(11):989-1002
  • Phase: 3
  • n: 1,961 (no T2D)
  • Duration: 68 weeks
  • Semaglutide: -14.9% mean body weight
  • Placebo: -2.4%. Trial supported the 2021 Wegovy FDA approval.

Read this before quoting either number

Different trials, not head-to-head in obesity. SURMOUNT-1 ran 72 weeks; STEP-1 ran 68 weeks. Different cohorts, different sponsors, different placebo response calibration. The 7.6 percentage-point gap is a data observation across trials, not a controlled head-to-head finding.

Note on SURPASS-2 (Frias et al, NEJM 2021): this was a head-to-head trial between tirzepatide and semaglutide, but in TYPE 2 DIABETES (not obesity), testing tirzepatide against the lower, diabetes-label semaglutide dose, over 40 weeks. In its highest dose group, tirzepatide reduced body weight 11.2kg vs semaglutide 5.7kg. Useful directional signal, but the patient population is T2D and the semaglutide comparator was the diabetes-label dose. SURPASS-2 is not a head-to-head obesity comparison.

FDA and regulatory status

Both compounds are FDA-approved as brand pens. This is the symmetric case in the /vs/* cluster.

Tirzepatide brand pens (Eli Lilly)

  • Mounjaro: FDA-approved May 13, 2022. Indication: type 2 diabetes.
  • Zepbound: FDA-approved Nov 8, 2023. Indication: chronic weight management.

Semaglutide brand pens (Novo Nordisk)

  • Ozempic: FDA-approved Dec 5, 2017. Indication: type 2 diabetes.
  • Wegovy: FDA-approved Jun 4, 2021. Indication: chronic weight management.

Peptara scope

The brand pens (Mounjaro, Zepbound, Ozempic, Wegovy) are FDA-approved finished pharmaceuticals available only via prescription in their approved markets. Peptara does not sell brand pens and does not sell semaglutide in any form.

Side effects

Both share the GI-dominant GLP-1 class profile. Notes below are not exhaustive.

Shared (GLP-1 class)

  • Nausea
  • Diarrhea
  • Constipation
  • Vomiting, more frequent in higher dose groups

Semaglutide-specific

  • Years of clinical safety data (SUSTAIN, SELECT)
  • FDA black-box warning: thyroid C-cell tumors (rodent data)
  • Gastroparesis case reports at high cumulative exposure
  • Rare pancreatitis and gallbladder events

Tirzepatide-specific

  • SURMOUNT-1: nausea about 30% in the highest dose group vs about 10% placebo
  • Lower hypoglycemia risk than insulin combinations (T2D context)
  • Same GLP-1 class thyroid C-cell black-box warning
  • GI events were dose-related in SURMOUNT-1

In both trials, gastrointestinal events were the most common adverse events and were mostly mild to moderate (Jastreboff et al., 2022; Wilding et al., 2021).

Frequently asked questions

Is tirzepatide really better than Ozempic for weight loss?

Phase 3 SURMOUNT-1 peak was -22.5% body weight in the highest dose group over 72 weeks for tirzepatide (Jastreboff et al, NEJM 2022). Phase 3 STEP-1 peak was -14.9% over 68 weeks for semaglutide / Wegovy (Wilding et al, NEJM 2021). The 7.6 percentage-point gap is a data observation across separate trials with different cohorts, different sponsors, different durations. The SURPASS-2 trial was head-to-head between tirzepatide and semaglutide, but in TYPE 2 DIABETES, against the lower, diabetes-label semaglutide dose, over 40 weeks: useful as a directional signal but not an obesity head-to-head.

Are Mounjaro and Zepbound the same as tirzepatide?

Yes. Both are brand-name tirzepatide manufactured by Eli Lilly. Mounjaro was FDA-approved May 2022 for type 2 diabetes. Zepbound was FDA-approved November 2023 specifically for chronic weight management in adults with BMI of 30 or higher (or 27 with a comorbidity). Same molecule, different on-label indications.

Are Ozempic and Wegovy the same as semaglutide?

Yes. Both are brand-name semaglutide from Novo Nordisk. Ozempic was FDA-approved December 2017 for type 2 diabetes. Wegovy was FDA-approved June 2021 for chronic weight management. Same molecule, different on-label indications.

Does Peptara sell Ozempic or Wegovy?

No. Peptara does NOT sell semaglutide in any form. Peptara is a research-peptide supplier; brand pens are finished pharmaceuticals available only via prescription. Anyone selling "Wegovy from Vietnam" online is selling gray-market product with no chain-of-custody guarantee.

What are the side effects of tirzepatide vs semaglutide?

Both share the GLP-1 class side-effect profile: nausea, diarrhea, constipation, vomiting. These events were more frequent in higher dose groups. SURMOUNT-1 reported nausea in roughly 30% of the highest dose group vs roughly 10% on placebo. Semaglutide has the longer safety record (SUSTAIN cardiovascular outcomes trial in T2D, SELECT cardiovascular trial in obesity). Both carry the GLP-1 class thyroid C-cell black-box warning (rodent signal; no confirmed human cases).

How does this compare to retatrutide?

Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon) currently in Phase 3 (TRIUMPH program, Eli Lilly). Phase 2 peak was -24.2% body weight in the highest dose group over 48 weeks (Jastreboff et al, NEJM 2023). Larger trial effect than both tirzepatide and semaglutide, but Phase 3 data is still being collected and retatrutide is not yet FDA-approved. See the Retatrutide vs Tirzepatide and Retatrutide vs Ozempic comparison pages for the full breakdowns.

Questions on tirzepatide vs Ozempic

Questions about the research? Message the Peptara Labs team on WhatsApp.

Chat with us